Opus Genetics Q3 EPS Raised by Brookline Capital Markets

Opus Genetics, Inc. (NASDAQ:IRD) – Equities researchers at Brookline Capital Markets increased their Q3 2026 earnings per share (EPS) estimates for Opus Genetics in a research report issued on Monday, August 10th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.18). The consensus estimate for Opus Genetics’ current full-year earnings is ($1.05) per share. Brookline Capital Markets also issued estimates for Opus Genetics’ FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at ($0.61) EPS and FY2029 earnings at ($0.71) EPS.

Other analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Opus Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Guggenheim assumed coverage on shares of Opus Genetics in a research note on Thursday, June 4th. They set a “buy” rating and a $16.00 price objective for the company. Zacks Research lowered shares of Opus Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Leerink Partners began coverage on shares of Opus Genetics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Citizens Jmp restated a “market outperform” rating and set a $11.00 target price on shares of Opus Genetics in a report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.69.

Opus Genetics Stock Down 3.1%

Shares of NASDAQ:IRD opened at $3.76 on Thursday. The company has a market cap of $310.76 million, a P/E ratio of -2.79 and a beta of 0.59. Opus Genetics has a 52 week low of $1.04 and a 52 week high of $5.81. The business has a fifty day simple moving average of $3.79 and a 200-day simple moving average of $4.15.

Opus Genetics (NASDAQ:IRD) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The company had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $2.63 million. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.

Insider Transactions at Opus Genetics

In other news, Director Fighting Blindness Foundation sold 1,700,000 shares of Opus Genetics stock in a transaction on Monday, May 18th. The stock was sold at an average price of $4.35, for a total transaction of $7,395,000.00. Following the transaction, the director directly owned 3,792,171 shares in the company, valued at approximately $16,495,943.85. This trade represents a 30.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO George Magrath sold 9,475 shares of the company’s stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the sale, the chief executive officer directly owned 1,731,869 shares of the company’s stock, valued at $5,109,013.55. The trade was a 0.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 1,729,331 shares of company stock worth $7,481,629. Insiders own 11.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in IRD. Blair William & Co. IL boosted its stake in Opus Genetics by 12.3% in the 4th quarter. Blair William & Co. IL now owns 27,466 shares of the company’s stock worth $55,000 after purchasing an additional 3,000 shares during the period. Raymond James Financial Inc. boosted its stake in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock worth $37,000 after acquiring an additional 11,000 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in shares of Opus Genetics in the 4th quarter valued at approximately $25,000. Stoneridge Investment Partners LLC bought a new stake in Opus Genetics during the second quarter worth approximately $47,000. Finally, State of Wyoming acquired a new position in Opus Genetics during the second quarter valued at approximately $65,000. 14.97% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $1.03 from $1.18 and its FY2027 forecast to a loss of $0.40 from $0.46. The firm also projects a smaller Q4 2026 loss of $0.09, followed by profitability in FY2029 and $0.27 EPS in FY2030. HC Wainwright maintained a Buy rating and an $8.00 price target, well above the stock’s recent trading level.
• Positive Sentiment: Brookline Capital Markets expects Opus Genetics to generate $0.62 EPS in FY2030, indicating potentially stronger long-term earnings power than HC Wainwright’s estimate.
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the report also showed an invalid percentage change, the data provides little meaningful indication of short-selling pressure.
• Negative Sentiment: Despite the improved forecasts, Opus Genetics is still expected to post substantial losses through FY2028, while the company’s current-year consensus estimate remains a loss of $1.09 per share. The lack of immediate earnings or revenue improvement may be limiting investor enthusiasm.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.